BR

BrightPath Biotherapeutics Co., Ltd.

A clinical-stage biopharma company developing cancer immunotherapies and cell therapies.

4594 | T

Overview

Corporate Details

ISIN(s):
JP3274140007
LEI:
Country:
Japan
Address:
川崎市川崎区殿町三丁目25番22号

Description

BrightPath Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company's core technology is its iPS-NKT platform, a novel allogeneic cell therapy that utilizes induced pluripotent stem cells (iPSCs) to produce large, homogeneous quantities of natural killer T (NKT) cells for cancer treatment. This proprietary approach is designed to overcome the natural scarcity of NKT cells, enabling the therapeutic application of their multifaceted anti-tumor effects. In addition to its cell therapy program, the company's development pipeline includes cancer peptide vaccines and immuno-modulating antibodies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2022-12-19 08:25
訂正有価証券報告書-第16期(平成30年4月1日-平成31年3月31日)
Japanese 748.7 KB
2022-12-19 08:23
訂正有価証券報告書-第17期(平成31年4月1日-令和2年3月31日)
Japanese 1023.6 KB
2022-12-19 08:22
訂正有価証券報告書-第18期(令和2年4月1日-令和3年3月31日)
Japanese 920.6 KB
2022-12-19 08:20
訂正有価証券報告書-第19期(令和3年4月1日-令和4年3月31日)
Japanese 551.9 KB
2022-11-11 07:16
確認書
Japanese 9.0 KB
2022-11-11 07:15
四半期報告書-第20期第2四半期(令和4年7月1日-令和4年9月30日)
Japanese 192.1 KB
2022-08-12 08:58
確認書
Japanese 9.0 KB
2022-08-12 08:05
四半期報告書-第20期第1四半期(令和4年4月1日-令和4年6月30日)
Japanese 159.1 KB
2022-06-23 08:05
内部統制報告書-第19期(令和3年4月1日-令和4年3月31日)
Japanese 23.1 KB
2022-06-23 08:04
確認書
Japanese 9.0 KB
2022-06-23 07:13
有価証券報告書-第19期(令和3年4月1日-令和4年3月31日)
Japanese 991.1 KB
2022-02-10 08:06
四半期報告書-第19期第3四半期(令和3年10月1日-令和3年12月31日)
Japanese 182.2 KB
2021-11-12 07:06
四半期報告書-第19期第2四半期(令和3年7月1日-令和3年9月30日)
Japanese 193.4 KB
2021-08-13 08:04
四半期報告書-第19期第1四半期(令和3年4月1日-令和3年6月30日)
Japanese 160.5 KB
2021-06-25 06:47
確認書
Japanese 9.0 KB

Automate Your Workflow. Get a real-time feed of all BrightPath Biotherapeutics Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BrightPath Biotherapeutics Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BrightPath Biotherapeutics Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Camurus Logo
Develops and commercializes long-acting medicines for severe and chronic diseases.
Sweden
CAMX
Candel Therapeutics, Inc. Logo
Develops viral immunotherapies to activate the immune system to fight cancer.
United States of America
CADL
Can-Fite BioPharma Ltd. Logo
Clinical-stage biopharma developing oral small-molecule drugs targeting the A3AR.
Israel
CANF
Cannabotech Ltd. Logo
Develops therapies by integrating cannabinoids and medicinal mushroom extracts.
Israel
CNTC
Cannovum Cannabis AG Logo
Licensed importer, wholesaler, and manufacturer of medical cannabis products.
Germany
27N0
Cantargia Logo
Develops antibody therapies targeting IL1RAP for cancer and inflammatory diseases.
Sweden
CANTA
Cantourage Group SE Logo
Produces and distributes EU-compliant medical cannabis from international partners.
Germany
HIGH
CAPRICOR THERAPEUTICS, INC. Logo
A clinical-stage biotech developing cell and exosome-based biologics for serious diseases.
United States of America
CAPR
A clinical-stage biotech developing regenerative medicines for heart failure.
United Kingdom
N/A
Cardiol Therapeutics Inc. Logo
Clinical-stage company developing anti-inflammatory and anti-fibrotic heart therapies.
United States of America
CRDL

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.